Figure 3.

(A) The effect of bicalutamide on the growth of HP-LNCaP xenografts. Each mouse received s.c. inoculation at one site in each flank with 100 μl of HP-LNCaP cells suspended in Matrigel. On tumour formation, mice were grouped and injected daily with vehicle (n=15) or bicalutamide (n=15) (100 mg kg⁻¹ q.d. s.c.). Measurements began at ∼400 mm³ and tumour volumes were measured weekly. Five mice from each group were isolated and killed at weeks 2, 3, and 4 for tumour and PSA analysis. Tumour growth rates were not significantly different between bicalutamide treatment and control groups. (B) Expression of signalling proteins in tumour lysates from HP-LNCaP xenografts. Mice described above in A were treated with vehicle (n=10) and bicalutamide (n=10). Tumours were collected at weeks 2, 3, and 4 of treatment. Western immunoblotting analysis is described in Materials and Methods. (C) Serum PSA levels of HP-LNCaP xenografts. Total PSA ELISA from the serum of HP-LNCaP xenografts treated with vehicle or bicalutamide for 2, 3, or 4 weeks. The experimental protocol is described in Materials and Methods. The PSA values for bicalutamide-treated mice were statistically significantly different from controls at all weeks of treatment (P<0.005).